Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength

Bristol-Myers Squibb Company ( BMY ) shares have risen 27.7% since my last article , "Why Bristol-Myers Squibb Remains Undervalued In 2025," in mid-November. They have outperformed the S&P 500 [3.6% return] ( SPY ) during that time.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, techno ...